Beth Sandy, MSN, CRNP

The FDA expands accelerated approval for sevabertinib to frontline HER2-mutant NSCLC, highlighting a need for vigilant nursing management of diarrhea.

Beth Sandy, CRNP, of Penn Medicine explains how oncology nurses and pharmacists collaborate to manage financial toxicity and secure oral therapies.

Beth Sandy, MSN, CRNP, discusses the application of 2 FDA approved drugs for patients with non–small cell lung cancer and an exon 20 insertion mutation.